cross-posted from: https://exploding-heads.com/post/121147

Seven years have passed since the FDA gave its blessing for the Targeting Aging with Metformin (TAME) clinical trial, the first trial to target the effects of aging. TAME is a double blind, placebo-controlled, multi-center study designed to evaluate whether the diabetes drug Metformin can protect against age-related conditions such as cancer, dementia or cardiovascular disease in non-diabetic study participants. The goal of the trial is to establish an indication for aging, which the American Federation of Aging Research refers to as a “proof of concept” that aging is an appropriate drug target.